Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

TRO40303 Ameliorates Alcohol-Induced Pancreatitis Through Reduction of Fatty Acid Ethyl Ester-Induced Mitochondrial Injury and Necrotic Cell Death.

Javed MA, Wen L, Awais M, Latawiec D, Huang W, Chvanov M, Schaller S, Bordet T, Michaud M, Pruss R, Tepikin A, Criddle D, Sutton R.

Pancreas. 2018 Jan;47(1):18-24. doi: 10.1097/MPA.0000000000000953.

2.

Olesoxime favors oligodendrocyte differentiation through a functional interplay between mitochondria and microtubules.

Magalon K, Le Grand M, El Waly B, Moulis M, Pruss R, Bordet T, Cayre M, Belenguer P, Carré M, Durbec P.

Neuropharmacology. 2016 Dec;111:293-303. doi: 10.1016/j.neuropharm.2016.09.009. Epub 2016 Sep 13.

PMID:
27618742
3.

Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.

Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JC, Jansson EK, Eckert GP, Pichler BJ, Bordet T, Pruss RM, Riess O, Nguyen HP.

Brain. 2015 Dec;138(Pt 12):3632-53. doi: 10.1093/brain/awv290. Epub 2015 Oct 21.

PMID:
26490331
4.

TRO40303, a mitochondrial-targeted cytoprotective compound, provides protection in hepatitis models.

Schaller S, Michaud M, Latyszenok V, Robert F, Hocine M, Arnoux T, Gabriac M, Codoul H, Bourhane A, de Bellefois IC, Afxantidis J, Pruss RM.

Pharmacol Res Perspect. 2015 Jun;3(3):e00144. doi: 10.1002/prp2.144. Epub 2015 May 8.

5.

Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP.

Mukherjee R, Mareninova OA, Odinokova IV, Huang W, Murphy J, Chvanov M, Javed MA, Wen L, Booth DM, Cane MC, Awais M, Gavillet B, Pruss RM, Schaller S, Molkentin JD, Tepikin AV, Petersen OH, Pandol SJ, Gukovsky I, Criddle DN, Gukovskaya AS, Sutton R; NIHR Pancreas Biomedical Research Unit.

Gut. 2016 Aug;65(8):1333-46. doi: 10.1136/gutjnl-2014-308553. Epub 2015 Jun 12. Erratum in: Gut. 2019 Jun;68(6):1136.

6.

Differences in the profile of protection afforded by TRO40303 and mild hypothermia in models of cardiac ischemia/reperfusion injury.

Hansson MJ, Llwyd O, Morin D, de Paulis D, Arnoux T, Gouarné C, Koul S, Engblom H, Bordet T, Tissier R, Arheden H, Erlinge D, Halestrap AP, Berdeaux A, Pruss RM, Schaller S.

Eur J Pharmacol. 2015 Aug 5;760:7-19. doi: 10.1016/j.ejphar.2015.04.009. Epub 2015 Apr 17.

PMID:
25895640
7.

Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells.

Gouarné C, Tracz J, Paoli MG, Deluca V, Seimandi M, Tardif G, Xilouri M, Stefanis L, Bordet T, Pruss RM.

Br J Pharmacol. 2015 Jan;172(1):235-45. doi: 10.1111/bph.12939. Epub 2014 Dec 1.

8.

Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results.

Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen P, Cuvier V, Danchin N, Dubois-Randé JL, Engblom H, Erlinge D, Firat H, Halvorsen S, Hansen HS, Hauke W, Heiberg E, Koul S, Larsen AI, Le Corvoisier P, Nordrehaug JE, Paganelli F, Pruss RM, Rousseau H, Schaller S, Sonou G, Tuseth V, Veys J, Vicaut E, Jensen SE.

Eur Heart J. 2015 Jan 7;36(2):112-9. doi: 10.1093/eurheartj/ehu331. Epub 2014 Sep 1.

PMID:
25179768
9.

Tissue- and cell-specific mitochondrial defect in Parkin-deficient mice.

Damiano M, Gautier CA, Bulteau AL, Ferrando-Miguel R, Gouarne C, Paoli MG, Pruss R, Auchère F, L'Hermitte-Stead C, Bouillaud F, Brice A, Corti O, Lombès A.

PLoS One. 2014 Jun 24;9(6):e99898. doi: 10.1371/journal.pone.0099898. eCollection 2014.

10.

Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.

Richter F, Gao F, Medvedeva V, Lee P, Bove N, Fleming SM, Michaud M, Lemesre V, Patassini S, De La Rosa K, Mulligan CK, Sioshansi PC, Zhu C, Coppola G, Bordet T, Pruss RM, Chesselet MF.

Neurobiol Dis. 2014 Sep;69:263-75. doi: 10.1016/j.nbd.2014.05.012. Epub 2014 May 18.

11.

Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.

Eckmann J, Clemens LE, Eckert SH, Hagl S, Yu-Taeger L, Bordet T, Pruss RM, Muller WE, Leuner K, Nguyen HP, Eckert GP.

Mol Neurobiol. 2014 Aug;50(1):107-18. doi: 10.1007/s12035-014-8663-3. Epub 2014 Mar 18.

PMID:
24633813
12.

Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial.

Le Lamer S, Paradis S, Rahmouni H, Chaimbault C, Michaud M, Culcasi M, Afxantidis J, Latreille M, Berna P, Berdeaux A, Pietri S, Morin D, Donazzolo Y, Abitbol JL, Pruss RM, Schaller S.

J Transl Med. 2014 Feb 7;12:38. doi: 10.1186/1479-5876-12-38.

13.

A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.

Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, Meininger V; Mitotarget study group.

Eur J Neurol. 2014 Mar;21(3):529-36. doi: 10.1111/ene.12344. Epub 2014 Jan 21.

PMID:
24447620
14.

Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease.

Gouarné C, Tardif G, Tracz J, Latyszenok V, Michaud M, Clemens LE, Yu-Taeger L, Nguyen HP, Bordet T, Pruss RM.

PLoS One. 2013 Nov 26;8(11):e81528. doi: 10.1371/journal.pone.0081528. eCollection 2013.

15.

Mitochondrial translocator protein (TSPO) ligands prevent doxorubicin-induced mechanical dysfunction and cell death in isolated cardiomyocytes.

de Tassigny Ad, Assaly R, Schaller S, Pruss RM, Berdeaux A, Morin D.

Mitochondrion. 2013 Nov;13(6):688-97. doi: 10.1016/j.mito.2013.10.001. Epub 2013 Oct 11.

16.

Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF.

Gouarné C, Giraudon-Paoli M, Seimandi M, Biscarrat C, Tardif G, Pruss RM, Bordet T.

Br J Pharmacol. 2013 Apr;168(8):1975-88. doi: 10.1111/bph.12094.

17.

Developments in the discovery of drugs for spinal muscular atrophy: successful beginnings and future prospects.

Pruss RM.

Expert Opin Drug Discov. 2011 Aug;6(8):827-37. doi: 10.1517/17460441.2011.586692. Epub 2011 May 21.

PMID:
22651125
18.

Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model.

Sunyach C, Michaud M, Arnoux T, Bernard-Marissal N, Aebischer J, Latyszenok V, Gouarné C, Raoul C, Pruss RM, Bordet T, Pettmann B.

Neuropharmacology. 2012 Jun;62(7):2346-52. doi: 10.1016/j.neuropharm.2012.02.013. Epub 2012 Feb 20.

PMID:
22369784
19.

Olesoxime accelerates myelination and promotes repair in models of demyelination.

Magalon K, Zimmer C, Cayre M, Khaldi J, Bourbon C, Robles I, Tardif G, Viola A, Pruss RM, Bordet T, Durbec P.

Ann Neurol. 2012 Feb;71(2):213-26. doi: 10.1002/ana.22593.

PMID:
22367994
20.

Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development.

Pruss RM, Giraudon-Paoli M, Morozova S, Berna P, Abitbol JL, Bordet T.

Future Med Chem. 2010 Sep;2(9):1429-40. doi: 10.4155/fmc.10.228.

22.

Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells.

Rovini A, Carré M, Bordet T, Pruss RM, Braguer D.

Biochem Pharmacol. 2010 Sep 15;80(6):884-94. doi: 10.1016/j.bcp.2010.04.018. Epub 2010 Apr 22.

PMID:
20417191
23.

TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition.

Schaller S, Paradis S, Ngoh GA, Assaly R, Buisson B, Drouot C, Ostuni MA, Lacapere JJ, Bassissi F, Bordet T, Berdeaux A, Jones SP, Morin D, Pruss RM.

J Pharmacol Exp Ther. 2010 Jun;333(3):696-706. doi: 10.1124/jpet.110.167486. Epub 2010 Mar 9.

PMID:
20215409
24.

Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound.

Bordet T, Berna P, Abitbol JL, Pruss RM.

Pharmaceuticals (Basel). 2010 Jan 28;3(2):345-368. Review.

25.

Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy.

Michaud M, Arnoux T, Bielli S, Durand E, Rotrou Y, Jablonka S, Robert F, Giraudon-Paoli M, Riessland M, Mattei MG, Andriambeloson E, Wirth B, Sendtner M, Gallego J, Pruss RM, Bordet T.

Neurobiol Dis. 2010 Apr;38(1):125-35. doi: 10.1016/j.nbd.2010.01.006. Epub 2010 Jan 18.

PMID:
20085811
26.

Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel.

Xiao WH, Zheng FY, Bennett GJ, Bordet T, Pruss RM.

Pain. 2009 Dec 15;147(1-3):202-9. doi: 10.1016/j.pain.2009.09.006. Epub 2009 Oct 14.

27.

Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Bordet T, Pruss RM.

Neurotherapeutics. 2009 Oct;6(4):648-62. doi: 10.1016/j.nurt.2009.07.001. Review.

28.

Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy.

Bordet T, Buisson B, Michaud M, Abitbol JL, Marchand F, Grist J, Andriambeloson E, Malcangio M, Pruss RM.

J Pharmacol Exp Ther. 2008 Aug;326(2):623-32. doi: 10.1124/jpet.108.139410. Epub 2008 May 20.

PMID:
18492948
29.

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis.

Bordet T, Buisson B, Michaud M, Drouot C, Galéa P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, Lacapère JJ, Massaad C, Schumacher M, Steidl EM, Maux D, Delaage M, Henderson CE, Pruss RM.

J Pharmacol Exp Ther. 2007 Aug;322(2):709-20. Epub 2007 May 11.

PMID:
17496168
30.

Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease.

Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, Olson JM, Sipione S, Tartari M, Cattaneo E.

J Neurosci. 2005 Oct 26;25(43):9932-9.

31.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J, Guitard J, Gout G, Steinberg R, Rodier D, Griebel G, Soubrie P, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Apr;301(1):322-32.

PMID:
11907190
32.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
33.

Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site.

Heitz F, Holzwarth JA, Gies JP, Pruss RM, Trumpp-Kallmeyer S, Hibert MF, Guenet C.

Eur J Pharmacol. 1999 Sep 10;380(2-3):183-95.

PMID:
10513578
34.

The rat mGlu1d receptor splice variant shares functional properties with the other short isoforms of mGlu1 receptor.

Mary S, Stephan D, Gomeza J, Bockaert J, Pruss RM, Pin JP.

Eur J Pharmacol. 1997 Sep 17;335(1):65-72.

PMID:
9371547
35.

Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants.

Stephan D, Bon C, Holzwarth JA, Galvan M, Pruss RM.

Neuropharmacology. 1996;35(12):1649-60.

PMID:
9076744
36.
37.

Galanin gene expression in chromaffin cells is controlled by calcium and protein kinase signaling pathways.

Rökaeus A, Pruss RM, Eiden LE.

Endocrinology. 1990 Dec;127(6):3096-102.

PMID:
1701135
40.
41.
42.

Characterization of the altered oligosaccharide composition of the insulin receptor on neural-derived cells.

Ota A, Shemer J, Pruss RM, Lowe WL Jr, LeRoith D.

Brain Res. 1988 Mar 8;443(1-2):1-11.

PMID:
3359262
43.

Functional insulin-like growth factor I receptors are expressed by neural-derived continuous cell lines.

Ota A, Wilson GL, Spilberg O, Pruss R, LeRoith D.

Endocrinology. 1988 Jan;122(1):145-52.

PMID:
2961554
44.

A tachykinin peptide receptor joins an elite club.

Buck SH, Pruss RM, Krstenansky JL, Robinson PJ, Stauderman KA.

Trends Pharmacol Sci. 1988 Jan;9(1):3-5. Review. No abstract available.

PMID:
2854311
45.

The regulation of vasoactive intestinal peptide synthesis in neuroblastoma and chromaffin cells.

Beinfeld MC, Brick PL, Howlett AC, Holt IL, Pruss RM, Moskal JR, Eiden LE.

Ann N Y Acad Sci. 1988;527:68-76. Review. No abstract available.

PMID:
2839090
46.
49.

Regulation of enkephalin, VIP, and chromogranin biosynthesis in actively secreting chromaffin cells. Multiple strategies for multiple peptides.

Waschek JA, Pruss RM, Siegel RE, Eiden LE, Bader MF, Aunis D.

Ann N Y Acad Sci. 1987;493:308-23.

PMID:
3035984
50.

Enkephalin and neuropeptide Y: two colocalized neuropeptides are independently regulated in primary cultures of bovine chromaffin cells.

Pruss RM, Mezey E, Forman DS, Eiden LE, Hotchkiss AJ, DiMaggio DA, O'Donohue TL.

Neuropeptides. 1986 May-Jun;7(4):315-27.

PMID:
3755510

Supplemental Content

Support Center